Breaking News

FDA Approves New Targeted Drug for Leukemia Tested at University of Pennsylvania

The U.S. Food and Drug Administration (FDA) has approved the first ever inhibitor drug specifically approved for treating patients with relapsed or refractory acute myeloid leukemia (AML) with a mutation in the Fms-like tyrosine kinase 3 (FLT3) gene.

On the News Blog

Penn Medicine In the News

  • Researchers Discover New Skin Regeneration Mechanism

    December 04, 2018
  • Telemedicine Offers New Health Care Possibilities, But Payment Challenges Abound

    December 04, 2018
  • Strong Longer-Term Kymriah Data at ASH 2018

    December 03, 2018
  • Four Days of Intensive Therapy Can Reverse OCD for Years

    November 29, 2018
  • Forget Your Washboard Abs, the Hottest Workout Is for Your Fingers

    November 28, 2018
  • FDA Approves Targeted Drug to Treat Relapsed or Refractory AML with FLT3 Mutation

    November 03, 2018
Share This Page: